SHARPIN

Sharpin (Shank-associated RH domain-interacti · Q9H0F6 · SHARPIN on Sugi Atlas →

63 patent compounds predicted against SHARPIN, 47 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gliotoxin (SCHEMBL54420)	1.00	1/20
Gliotoxin (SCHEMBL4294337)	1.00	1/20
Gliotoxin (SCHEMBL9667270)	1.00	1/20
Gliotoxin (SCHEMBL12018743)	1.00	1/20
Gliotoxin (SCHEMBL12149513)	1.00	1/20
Gliotoxin (SCHEMBL12618354)	1.00	1/20
Gliotoxin (SCHEMBL13341245)	1.00	1/20
Gliotoxin (SCHEMBL14514067)	1.00	1/20
Gliotoxin (SCHEMBL14579856)	1.00	1/20
Gliotoxin (SCHEMBL14986985)	1.00	1/20
Gliotoxin (SCHEMBL20199940)	1.00	1/20
Gliotoxin G (SCHEMBL30567451)	0.88	1/20
SCHEMBL12901998	0.84	1/20
SCHEMBL14021819	0.84	1/20
SCHEMBL25722212	0.82	1/20
Gliotoxin (SCHEMBL6934245)	0.73	1/20
Gliotoxin (SCHEMBL4735750)	0.71	1/20
Gliotoxin (SCHEMBL14332623)	0.71	1/20
SCHEMBL18652980	0.66	1/20
SCHEMBL17971336	0.64	1/20

Clinical trials — most relevant to SHARPIN by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Tumor Gene Expression in Women With Ovarian Cancer	PHASE4	COMPLETED
FITMI - First In Treating Male Infertility	PHASE2	ACTIVE_NOT_RECRUITING
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination	PHASE1/PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
NAPO - Novel Approach for Oligospermia	PHASE1/PHASE2	COMPLETED
Effects of Gum Arabic on Metabolic Syndrome Parameters in Postmenopausal Women	PHASE2	COMPLETED
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia	EARLY_PHASE1	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Asprosın And Tumor Necrosıs Factor-α Levels In Type 2 Dıabetıc Chronıc Periodontitis	nan	COMPLETED
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study	nan	COMPLETED
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches	nan	UNKNOWN
BAFF Levels and Lupus Nephritis (LN)	nan	WITHDRAWN
DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Effect of Smoking on Periodontal Therapy in Periodontitis	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Role of Vaspin in Pathophysiology of Pre-eclampsia	nan	UNKNOWN
Value of Various Chemokines in the Detection and Follow up of RCC	nan	UNKNOWN
Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus	nan	COMPLETED
RNA Cloning and Visualization in Human Atherosclerosis	nan	COMPLETED
Adenosylmethionine Metabolism in Human Inflammation	nan	UNKNOWN
Exercise and the Receptor for Advanced Glycation End Products (RAGE)	nan	COMPLETED
Diagnostic and Prognostic Value of MicroRNA in Breast Cancer Patients	nan	UNKNOWN
Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SHARPIN binder may also engage these)

Protein	Name	Similarity
E1BDF2	—	0.990	E1BDF2 →
Q91WA6	—	0.988	Q91WA6 →
Q9EQL9	—	0.981	Q9EQL9 →
Q86UR1	—	0.979	Q86UR1 →
Q0IIA6	—	0.977	Q0IIA6 →
Q8NAG6	—	0.976	Q8NAG6 →
Q96N21	—	0.976	Q96N21 →
Q8IUW3	—	0.974	Q8IUW3 →
Q3B7L1	—	0.974	Q3B7L1 →
Q8N398	—	0.974	Q8N398 →
Q8N1F8	—	0.974	Q8N1F8 →
B2RYG7	—	0.973	B2RYG7 →
Q7L591	—	0.973	Q7L591 →
Q7Z736	—	0.972	Q7Z736 →
NOXO1	NADPH oxidase organizer 1	0.972	landscape →
Q9QZK7	—	0.972	Q9QZK7 →
Q3UR97	—	0.972	Q3UR97 →
Q8VCE9	—	0.972	Q8VCE9 →
Q861W0	—	0.972	Q861W0 →
Q5U4P2	—	0.972	Q5U4P2 →
Q3UR50	—	0.971	Q3UR50 →
M0RDU0	—	0.970	M0RDU0 →
Q3TAA7	—	0.970	Q3TAA7 →
Q8C0R7	—	0.970	Q8C0R7 →
Q96G42	—	0.969	Q96G42 →
F5GYI3	—	0.969	F5GYI3 →
E9PGG2	—	0.969	E9PGG2 →
Q5VTJ3	—	0.969	Q5VTJ3 →
Q2TA57	—	0.969	Q2TA57 →
A3R064	—	0.969	A3R064 →